Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2003-10-24
2008-12-09
Kemmerer, Elizabeth C. (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600
Reexamination Certificate
active
07462349
ABSTRACT:
The invention is intended to adapt an already established clinical procedure for the treatment of multiple sclerosis (MS)—the use of beta interferon—to treat chronic human spinal cord injury. The present invention relates to the prevention of chronic inflammation and demyelination following spinal cord injury.
REFERENCES:
patent: 2003/0027755 (2003-02-01), Juan et al.
Ulbrich, et al, 2003, Trends in Pharmacological Science, 24(12): 640-647.
Johnson, et al, Scientific American, May 1994, 68-75.
L.A. Stone et al., :Characterization of MRI response to treatment with interferon beta-lb: Contrast-enhancing MRI lesion frequency as a primary outcome. Neurology, 49: 862-869, Sep. 1997.
S. Floris et al: Interferon-β directly influences monocyte infiltration into the central nervous system J. Neuroimmunology, 127: 69-79, 2002.
Kalderon N. and Fuks Z. Structural recovery in lesioned adult mammalian spinal cord by x-irradiation of the lesion site.Proc Natl Acad Sci USA(1996) 93: 11179-84.
Xu S., Koutcher J.A., Fuks Z., and Kalderon N. In vivo imaging (MRI) of the natural and the x-irradiation facilitated repair of the lesion in severed adult rat spinal cord,Soc. Nuerosci. Abstr., (1999) 25: 493.
Xu S., Fuks Z., Koutcher J.A., and Kalderon N. The natural temporary repair of the lesion in severed adult rat spinal cord as seen in vivo by MRI,Exp. Neurol., (2000) 163:295.
Xu S., Muruganandham M., Koutcher J. and Kalderon N. Progression of pathology after contusion injury in rat spinal cord: in vivo MRI studies,Soc. Neurosci Abstr., (2001) 27: 2118.
Muruganandham M., Xu S., Kalderon N. and Koutcher J.A. MRI evaluation of the onset of chronic inflammation after contusion injury in rat spinal cord.Proc. Intl. Soc. Mag. Reson. Med., (2002) 10.
Burrows M., Wade P.D. and Kalderon N. Critical events in the repair/decay fate of the contusion-injured rat spinal cord,2002 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, Online, (2002) Program No. 133.10.
De Vries H.E., Kuiper J., De Boer A.G., Van Berkel T.J.C., and Breimer D.D. The blood-brain barrier in neuroinflammatory diseases.Pharm Reviews(1997) 49: 143-55.
Popovich P.G., Horner P.J., Mullin B.B. and Stokes B.T. A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury.Exp Neurol(1996) 142: 258-75.
Tator C.H. and Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury.J Neurosurg(1997) 86: 483-492.
Mautes A.E.M., Weinzierl M.R., Donovan F. and Noble L.J. Vascular events after Spinal cord injury: Contribution to secondary pathogenesis.Phys Ther. (2000) 80:673-687.
C. N. Serhan et al. Resolution of Inflammation: state of the art, definitions and terms. The FASEB Journal (2007) 21:325-332.
Kemmerer Elizabeth C.
Sterner Richard J.
Wegert Sandra
LandOfFree
Beta interferon for the treatment of chronic spinal cord injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta interferon for the treatment of chronic spinal cord injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta interferon for the treatment of chronic spinal cord injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043672